ABSTRACT
Abstract
Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user's body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes. This device can be used in combination with a glucometer.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 12/452,484, filed Jan. 4, 2010, now U.S. Pat. No. 9,173,991, which is a 35 U.S.C. § 371 national stage entry of PCT/IL2008/000915, which has an international filing date of 2 Jul. 2008 and claims priority to U.S. Provisional Patent Application No. 60/958,220, filed on 2 Jul. 2007. The present application incorporates herein by reference the disclosure of each of the above-referenced applications in its entirety.
FIELD
The present invention relates to a devices and methods for sustained medical infusion of drugs, including but not limited to delivery of one or more injectable drugs. In some non-limiting examples, an insulin dispensing device can be coupled to a glucose monitoring device that can concomitantly deliver additional anti-diabetic injectable drugs or other drugs or substances.
BACKGROUND
Diabetes mellitus is a disease of major global importance that has increased in frequency at almost epidemic rates. The worldwide prevalence in 2006 is 170 million people and is predicted to at least double over the next 10-15 years. Diabetes is characterized by a chronically raised blood glucose concentration (hyperglycemia), due to a relative or absolute lack of the pancreatic hormone, insulin. Within the healthy pancreas, beta cells, located in the islets of Langerhans, continuously produce and secrete insulin according to the blood glucose levels, maintaining near constant glucose levels in the body.
Much of the burden of the disease to the user and to health care resources can occur due to long-term tissue complications that affect both the small blood vessels (microangiopathy, causing eye, kidney and nerve damage) and the large blood vessels (causing accelerated atherosclerosis, with increased rates of coronary heart disease, peripheral vascular disease and stroke). The Diabetes Control and Complications Trial (DCCT) has demonstrated that development and progression of the chronic complications of diabetes are greatly related to the degree of altered glycemia as quantified by determinations of glycohemoglobin (HbAlc). (DCCT Trial, N. Engl. J. Med 1993; 329: 977-986, UKPDS Trial, Lancet 1998; 352: 837-853. BMJ 1998; 317, (7160): 703-13 and the EDIC Trial, N. Engl. J. Med. 2005; 353, (25): 2643-53). Thus, maintaining normolycemia by frequent glucose measurements and adjustment of insulin delivery accordingly can be quite important.
The glycemic index (GI) is a ranking system for carbohydrates based on their effect on blood glucose levels in the first two hours. Table 1 shows a few examples of foods and their GI.
TABLE 1
Glycemic index ranges and classifications for selected foods.
Classification
GI Range
Examples
Low GI
55 or less
Most fruit and vegetables (but not potato),
oats, buckwheat, whole barley, All-bran
Medium GI
56-69
Sucrose, basmati rice
High GI
70 or more
Corn flakes, baked potato, jasmine rice,
white bread, white rice, Mars bar
An after-meal or post-prandial glycemic peak (hyperglycemia) is defined as the net rise in a patient's blood glucose concentration that occurs from before eating to the highest point after eating. The ADA goal for diabetic treatment is a glucose concentration level that is less than 180 mg dlâ³1 at approximately 1-2 hrs after the start of meal. Increasing evidence suggests that postprandial hyperglycemia is a contributing factor to the development of atherosclerosis. The postprandial phase can be characterized by a rapid and large increase in blood glucose levels. The association of postprandial âhyperglycemic spikesâ with the onset of cardiovascular complications has recently received much attention. Postprandial hyperglycemia can be a direct and independent risk factor for cardiovascular disease (CVD). The mechanisms through which acute hyperglycemia exerts its effects may be identified in the production of free radicals. Correcting the postprandial hyperglycemia may form part of the strategy for the prevention and management of CVDs in diabetes {Diabetes 2005; 54:1-7). Other, short term problems, such as for example tiredness, concentration difficulties, decreased desire to move, mood shifts, and enhanced hunger, can also be attributed to postprandial hyperglycemia. As such, prevention of post-prandial hyperglycemia can be quite important.
Currently, the strategies used by diabetic patients for prevention of post-prandial hyperglycemia are divided into lifestyle approaches and medicinal approaches. Lifestyle approaches are mainly dietary. For example, a patient's diet can be restricted to intake of food that convert slowly to glucose, such as high fiber food. Timing of insulin boluses can also help lower post-prandial hyperglycemic peaks. Medicinal approaches include agents such as exenatide (Byetta) and pramlintide acetate (Symlin).
Amylin is a second β-cell hormone that is co-localized and co-secreted with insulin in response to meals. Consequently, β-cell dysfunction in insulin-requiring subjects with type 1 or type 2 diabetes is characterized by a markedly impaired postprandial secretory response of both insulin and amylin. Amylin acts as a neuroendocrine hormone that complements the effects of insulin in postprandial glucose regulation through several centrally mediated effects that can include a suppression of postprandial glucagon secretion and a vagus-mediated regulation of gastric emptying, thereby helping to control the influx of endogenous and exogenous glucose, respectively. Amylin has also been shown to reduce food intake and body weight, consistent with an additional satiety effect. Consistent with these findings, mealtime amylin replacement, as an adjunctive therapy to insulin delivery, can improve metabolic control in diabetic subjects.
FIG. 1 shows the co-secretion of amylin and insulin in response to meals in a healthy subject. Both hormones are co-localized in the β-cells of the pancreas. β-cell dysfunction in insulin-requiring subjects with type 1 or type 2 diabetes is characterized by a markedly impaired postprandial secretory response of both insulin and amylin.
Native human amylin is typically not ideal for clinical use because of the peptide's poor solubility and propensity to aggregate. Pramlintide is a soluble, non-aggregating synthetic peptide analog of human amylin that has a potency at least equal to that of native amylin. Pramlintide in insulin-requiring subjects with diabetes has been shown, as an adjunct to insulin therapy, to correct postprandial hyperglucagonemia, slow the delivery of nutrients from the stomach to the small intestine, and, concomitantly, improve postprandial glucose excursions (Diab. Tech. Therp. 2002; 4(1):51-61).
Pramlintide can be injected subcutaneously with a standard insulin syringe, rendering the dosage flexible. For weight loss, maximum doses are administered and for normalizing postprandial glucose levels, lower doses are indicated. The dosing recommended by the manufacturer for normalizing post-prandial glucose levels are the following: starting with 2.5 units and increasing to 5 units, then 7.5 units, and 10 units before each meal if no nausea is encountered for three consecutive days.
FIG. 2 shows mean (±SE) values for seven-point glucose profiles performed before (open circles) and after 6 months (solid circles) of pramlintide therapy in patients with type 2 diabetics on insulin therapy. The blood glucose concentrations were assessed within 0.5 h before and 1.5-2 h after breakfast, lunch, and dinner and at bedtime. It can be seen that both fasting and postprandial glucose concentrations were significantly reduced compared to baseline (P<0.05). (Diabetes Technology & Therapeutics 2007; 9 (2): 191-99.)
Insulin pumps can be used to deliver rapid acting insulin to a diabetic patient 24 hours a day through a catheter placed under the skin (subcutaneously). The total daily insulin dose can be divided into basal and bolus doses. Basal insulin can be delivered continuously, semi-continuously, or periodically over 24 hours, thereby maintaining the blood glucose concentration level (namely, blood glucose levels) within a normal, desirable range between meals and overnight. Diurnal basal rates can be pre-programmed or manually changed according to various daily activities. Insulin bolus doses can be delivered before or after meals to counteract carbohydrates loads or during episodes of high blood glucose concentration levels.
SUMMARY
In a first aspect, a portable therapeutic fluid delivery device has a form factor that permits ambulatory use by a patient and includes a first reservoir for containing a first therapeutic fluid, a second reservoir for containing a second therapeutic fluid, at least one cannula disposed to penetrate the patient's skin to deliver the first and/or the second therapeutic fluid subcutaneously at a dosing rate and being in fluid communication with the first and/or second reservoir, at least one pumping mechanism that delivers the first therapeutic fluid from the first reservoir at a first dosing rate and delivers the second therapeutic fluid from the second reservoir at a second dosing rate to the at least one cannula and into the patient, and a processor that controls the at least one pumping mechanisms.
In a second interrelated aspect, an infusion system for dispensing at least insulin and a second anti-diabetic agent into a patient's body includes a drug dispensing means that comprises a first reservoir and a first dispensing means for dispensing insulin for infusion into the patient's body and a second reservoir and a second dispensing means for dispensing the second anti-diabetic agent for infusion into the patient's body; a sensing means that measures a glucose level in the patient's body; and a processor that receives data regarding the glucose level from the sensing means and controls the drug dispensing means to regulate the dispensing of insulin and the anti-diabetic agent according to the glucose level.
In a third interrelated aspect, a method for delivery of a therapeutic fluid to a user from a portable, ambulatory device, includes delivering a first therapeutic fluid from a first reservoir of the device to the user via at least one cannula at a first dosing rate, delivering a second therapeutic fluid from a second reservoir to the user via the at least one cannula at a second dosing rate, and controlling the first dosing rate and the second dosing rate to affect a diabetes state of the user. The controlling is performed by a processor in the portable, ambulatory device.
Various additional features of these and other aspects that are disclosed herein can optionally include, but are not limited to, the following. The at least one cannula can include a first cannula in fluid communication with the first reservoir and a second cannula in fluid communication with the second reservoir. The first dosing rate can be different from the second dosing rate. The at least one pumping mechanism can include a first pumping mechanism and a second pumping mechanism wherein the first pumping mechanism delivers the first fluid from the first reservoir and the second pumping mechanism delivers the second fluid from the second reservoir. A remote control unit can be included and itself include a user interface for entering commands and/or receiving data from the processor. A wireless communication module can be included in the portable device for communication between the processor and the remote control unit. A sensing apparatus can be included that measures at least one health related parameter of the patient. The sensing apparatus can be a glucose monitor that at least semi-continuously measures blood glucose concentration data for the patient and communicates the blood glucose concentration data to the processor and the processor can optionally control the first and/or the second dosing rate in response to the blood glucose concentration data. The first therapeutic fluid can be insulin, and the first dosing rate can include a basal dosing component and/or a bolus component. The bolus component is determined based on data from the sensing apparatus. If the sensing apparatus provides glucose concentration data, the processor can control the first and/or the second dosing rate in response to the glucose concentration data. The second therapeutic fluid can optionally be a glucagon, an exenatide, or an amylin analog which can optionally be pramlintide acetate. The first and/or the second dosing rate can be based on expected calorie and/or carbohydrate intake by the patient. Delivery of the second therapeutic fluid can optionally be for prevention of post prandial hyperglycemia and/or user weight loss. The second therapeutic fluid can be pramlintide, and the dosage of the pramlintide can be 10% of a total daily dose of insulin (TDD) before each meal. A tolerability of the user for the first and/or the second dosing rates can be determined by the processor.
The portable therapeutic fluid delivery device can optionally further include at least one disposable part and a reusable part that mate with each other to form a dispensing patch unit. The at least one disposable part can include the first reservoir and the second reservoir, and the reusable part can include the processor and a pumping mechanism of at least one of the first and the second pump mechanisms. At least one housing can be included to contain the first reservoir, the second reservoir, the at least one pumping mechanism, and the processor, and the portable device can also include a cradle unit with an attachment side for securing to the skin and a mating side that connects to the at least one housing. The at least one pumping mechanis
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 12/452,484, filed Jan. 4, 2010, now U.S. Pat. No. 9,173,991, which is a 35 U.S.C. § 371 national stage entry of PCT/IL2008/000915, which has an international filing date of 2 Jul. 2008 and claims priority to U.S. Provisional Patent Application No. 60/958,220, filed on 2 Jul. 2007. The present application incorporates herein by reference the disclosure of each of the above-referenced applications in its entirety.
FIELD
The present invention relates to a devices and methods for sustained medical infusion of drugs, including but not limited to delivery of one or more injectable drugs. In some non-limiting examples, an insulin dispensing device can be coupled to a glucose monitoring device that can concomitantly deliver additional anti-diabetic injectable drugs or other drugs or substances.
BACKGROUND
Diabetes mellitus is a disease of major global importance that has increased in frequency at almost epidemic rates. The worldwide prevalence in 2006 is 170 million people and is predicted to at least double over the next 10-15 years. Diabetes is characterized by a chronically raised blood glucose concentration (hyperglycemia), due to a relative or absolute lack of the pancreatic hormone, insulin. Within the healthy pancreas, beta cells, located in the islets of Langerhans, continuously produce and secrete insulin according to the blood glucose levels, maintaining near constant glucose levels in the body.
Much of the burden of the disease to the user and to health care resources can occur due to long-term tissue complications that affect both the small blood vessels (microangiopathy, causing eye, kidney and nerve damage) and the large blood vessels (causing accelerated atherosclerosis, with increased rates of coronary heart disease, peripheral vascular disease and stroke). The Diabetes Control and Complications Trial (DCCT) has demonstrated that development and progression of the chronic complications of diabetes are greatly related to the degree of altered glycemia as quantified by determinations of glycohemoglobin (HbAlc). (DCCT Trial, N. Engl. J. Med 1993; 329: 977-986, UKPDS Trial, Lancet 1998; 352: 837-853. BMJ 1998; 317, (7160): 703-13 and the EDIC Trial, N. Engl. J. Med. 2005; 353, (25): 2643-53). Thus, maintaining normolycemia by frequent glucose measurements and adjustment of insulin delivery accordingly can be quite important.
The glycemic index (GI) is a ranking system for carbohydrates based on their effect on blood glucose levels in the first two hours. Table 1 shows a few examples of foods and their GI.
TABLE 1
Glycemic index ranges and classifications for selected foods.
Classification
GI Range
Examples
Low GI
55 or less
Most fruit and vegetables (but not potato),
oats, buckwheat, whole barley, All-bran
Medium GI
56-69
Sucrose, basmati rice
High GI
70 or more
Corn flakes, baked potato, jasmine rice,
white bread, white rice, Mars bar
An after-meal or post-prandial glycemic peak (hyperglycemia) is defined as the net rise in a patient's blood glucose concentration that occurs from before eating to the highest point after eating. The ADA goal for diabetic treatment is a glucose concentration level that is less than 180 mg dlâ³1 at approximately 1-2 hrs after the start of meal. Increasing evidence suggests that postprandial hyperglycemia is a contributing factor to the development of atherosclerosis. The postprandial phase can be characterized by a rapid and large increase in blood glucose levels. The association of postprandial âhyperglycemic spikesâ with the onset of cardiovascular complications has recently received much attention. Postprandial hyperglycemia can be a direct and independent risk factor for cardiovascular disease (CVD). The mechanisms through which acute hyperglycemia exerts its effects may be identified in the production of free radicals. Correcting the postprandial hyperglycemia may form part of the strategy for the prevention and management of CVDs in diabetes {Diabetes 2005; 54:1-7). Other, short term problems, such as for example tiredness, concentration difficulties, decreased desire to move, mood shifts, and enhanced hunger, can also be attributed to postprandial hyperglycemia. As such, prevention of post-prandial hyperglycemia can be quite important.
Currently, the strategies used by diabetic patients for prevention of post-prandial hyperglycemia are divided into lifestyle approaches and medicinal approaches. Lifestyle approaches are mainly dietary. For example, a patient's diet can be restricted to intake of food that convert slowly to glucose, such as high fiber food. Timing of insulin boluses can also help lower post-prandial hyperglycemic peaks. Medicinal approaches include agents such as exenatide (Byetta) and pramlintide acetate (Symlin).
Amylin is a second β-cell hormone that is co-localized and co-secreted with insulin in response to meals. Consequently, β-cell dysfunction in insulin-requiring subjects with type 1 or type 2 diabetes is characterized by a markedly impaired postprandial secretory response of both insulin and amylin. Amylin acts as a neuroendocrine hormone that complements the effects of insulin in postprandial glucose regulation through several centrally mediated effects that can include a suppression of postprandial glucagon secretion and a vagus-mediated regulation of gastric emptying, thereby helping to control the influx of endogenous and exogenous glucose, respectively. Amylin has also been shown to reduce food intake and body weight, consistent with an additional satiety effect. Consistent with these findings, mealtime amylin replacement, as an adjunctive therapy to insulin delivery, can improve metabolic control in diabetic subjects.
FIG. 1 shows the co-secretion of amylin and insulin in response to meals in a healthy subject. Both hormones are co-localized in the β-cells of the pancreas. β-cell dysfunction in insulin-requiring subjects with type 1 or type 2 diabetes is characterized by a markedly impaired postprandial secretory response of both insulin and amylin.
Native human amylin is typically not ideal for clinical use because of the peptide's poor solubility and propensity to aggregate. Pramlintide is a soluble, non-aggregating synthetic peptide analog of human amylin that has a potency at least equal to that of native amylin. Pramlintide in insulin-requiring subjects with diabetes has been shown, as an adjunct to insulin therapy, to correct postprandial hyperglucagonemia, slow the delivery of nutrients from the stomach to the small intestine, and, concomitantly, improve postprandial glucose excursions (Diab. Tech. Therp. 2002; 4(1):51-61).
Pramlintide can be injected subcutaneously with a standard insulin syringe, rendering the dosage flexible. For weight loss, maximum doses are administered and for normalizing postprandial glucose levels, lower doses are indicated. The dosing recommended by the manufacturer for normalizing post-prandial glucose levels are the following: starting with 2.5 units and increasing to 5 units, then 7.5 units, and 10 units before each meal if no nausea is encountered for three consecutive days.
FIG. 2 shows mean (±SE) values for seven-point glucose profiles performed before (open circles) and after 6 months (solid circles) of pramlintide therapy in patients with type 2 diabetics on insulin therapy. The blood glucose concentrations were assessed within 0.5 h before and 1.5-2 h after breakfast, lunch, and dinner and at bedtime. It can be seen that both fasting and postprandial glucose concentrations were significantly reduced compared to baseline (P<0.05). (Diabetes Technology & Therapeutics 2007; 9 (2): 191-99.)
Insulin pumps can be used to deliver rapid acting insulin to a diabetic patient 24 hours a day through a catheter placed under the skin (subcutaneously). The total daily insulin dose can be divided into basal and bolus doses. Basal insulin can be delivered continuously, semi-continuously, or periodically over 24 hours, thereby maintaining the blood glucose concentration level (namely, blood glucose levels) within a normal, desirable range between meals and overnight. Diurnal basal rates can be pre-programmed or manually changed according to various daily activities. Insulin bolus doses can be delivered before or after meals to counteract carbohydrates loads or during episodes of high blood glucose concentration levels.
SUMMARY
In a first aspect, a portable therapeutic fluid delivery device has a form factor that permits ambulatory use by a patient and includes a first reservoir for containing a first therapeutic fluid, a second reservoir for containing a second therapeutic fluid, at least one cannula disposed to penetrate the patient's skin to deliver the first and/or the second therapeutic fluid subcutaneously at a dosing rate and being in fluid communication with the first and/or second reservoir, at least one pumping mechanism that delivers the first therapeutic fluid from the first reservoir at a first dosing rate and delivers the second therapeutic fluid from the second reservoir at a second dosing rate to the at least one cannula and into the patient, and a processor that controls the at least one pumping mechanisms.
In a second interrelated aspect, an infusion system for dispensing at least insulin and a second anti-diabetic agent into a patient's body includes a drug dispensing means that comprises a first reservoir and a first dispensing means for dispensing insulin for infusion into the patient's body and a second reservoir and a second dispensing means for dispensing the second anti-diabetic agent for infusion into the patient's body; a sensing means that measures a glucose level in the patient's body; and a processor that receives data regarding the glucose level from the sensing means and controls the drug dispensing means to regulate the dispensing of insulin and the anti-diabetic agent according to the glucose level.
In a third interrelated aspect, a method for delivery of a therapeutic fluid to a user from a portable, ambulatory device, includes delivering a first therapeutic fluid from a first reservoir of the device to the user via at least one cannula at a first dosing rate, delivering a second therapeutic fluid from a second reservoir to the user via the at least one cannula at a second dosing rate, and controlling the first dosing rate and the second dosing rate to affect a diabetes state of the user. The controlling is performed by a processor in the portable, ambulatory device.
Various additional features of these and other aspects that are disclosed herein can optionally include, but are not limited to, the following. The at least one cannula can include a first cannula in fluid communication with the first reservoir and a second cannula in fluid communication with the second reservoir. The first dosing rate can be different from the second dosing rate. The at least one pumping mechanism can include a first pumping mechanism and a second pumping mechanism wherein the first pumping mechanism delivers the first fluid from the first reservoir and the second pumping mechanism delivers the second fluid from the second reservoir. A remote control unit can be included and itself include a user interface for entering commands and/or receiving data from the processor. A wireless communication module can be included in the portable device for communication between the processor and the remote control unit. A sensing apparatus can be included that measures at least one health related parameter of the patient. The sensing apparatus can be a glucose monitor that at least semi-continuously measures blood glucose concentration data for the patient and communicates the blood glucose concentration data to the processor and the processor can optionally control the first and/or the second dosing rate in response to the blood glucose concentration data. The first therapeutic fluid can be insulin, and the first dosing rate can include a basal dosing component and/or a bolus component. The bolus component is determined based on data from the sensing apparatus. If the sensing apparatus provides glucose concentration data, the processor can control the first and/or the second dosing rate in response to the glucose concentration data. The second therapeutic fluid can optionally be a glucagon, an exenatide, or an amylin analog which can optionally be pramlintide acetate. The first and/or the second dosing rate can be based on expected calorie and/or carbohydrate intake by the patient. Delivery of the second therapeutic fluid can optionally be for prevention of post prandial hyperglycemia and/or user weight loss. The second therapeutic fluid can be pramlintide, and the dosage of the pramlintide can be 10% of a total daily dose of insulin (TDD) before each meal. A tolerability of the user for the first and/or the second dosing rates can be determined by the processor.
The portable therapeutic fluid delivery device can optionally further include at least one disposable part and a reusable part that mate with each other to form a dispensing patch unit. The at least one disposable part can include the first reservoir and the second reservoir, and the reusable part can include the processor and a pumping mechanism of at least one of the first and the second pump mechanisms. At least one housing can be included to contain the first reservoir, the second reservoir, the at least one pumping mechanism, and the processor, and the portable device can also include a cradle unit with an attachment side for securing to the skin and a mating side that connects to the at least one housing. The at least one pumping mechanism can include a piston-type displacement pumping mechanism that comprises a propelling plunger and/or the at least one pumping mechanism can include a peristaltic pumping mechanism. At least one of the first and the second reservoirs can be collapsible such that it changes volume according to the volume of the therapeutic fluid contained therein. The first reservoir can be coupled to a first housing and the second reservoir can be coupled to a second housing. Alternatively, the first reservoir and the second reservoir can be coupled to a single housing. One or more buttons can be included via which the patient can adjust the first and/or the second dosing rate.
Various features of the current subject matter can provide one or more benefits and/or advantages that can include, but are not limited to provision of a device that can dispense insulin and one or more additional injectable anti diabetic drugs (such as for example an amylin analog like pramlintide) to prevent post-prandial hyperglycemia and achieve a better glycemic control for a diabetic patient. The current subject matter can also be used in other applications in which delivery of more than one therapeutic fluid, formulation, or other substance to a patient or subject is desirable. One or more sensing apparati or other sensing data streams can be incorporated with the current subject matter to provide real time or near real time measurement of one or more factors that might impact the desired dose of the one or more therapeutic fluids to be delivered. Automated control, or alternatively automated alerting that user action is required can be provided in response to these measurements to allow prompt dosing of a therapeutic fluid in response to a measured body condition, such as for example an elevated or depressed blood glucose level. A continuous subcutaneous insulin infusion device can be provided that infuses basal insulin dosages and pre-meal bolus insulin dosages. In addition, the infusion device can comprise a pramlintide subcutaneous infusion mechanism that allows the user to administer the amylin analog before a meal and prevent post-prandial hyperglycemia. Devices according to various implementations of the current subject matter can be miniature, discreet, and economical for the user and highly cost effective. Relatively expensive components of such devices can optionally be provided in a reusable part that mates with a disposable part that contains relatively inexpensive components that can be discarded and replaced more frequently.
The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims.
For the purposes of promoting an understanding of the subject matter described herein, which can include one or more features and variations as described below, references may be made to specific implementations having discrete feature sets. The terminology used herein is for the purpose of describing particular implementations only, and is not intended to limit the scope of either the disclosed subject matter or of the particular inventions that are claimed below. For example, references to the delivery of insulin and/or the treatment of diabetes are intended to serve as illustrative examples of broader inventive concepts. Use of other therapeutic fluids, either in addition to or in place of insulin, as well as materials and apparatuses compatible with the same, are within the contemplated scope of the current subject matter. Additionally, as used throughout this disclosure, the singular articles âa,â âan,â and âtheâ are intended to include both singular and plural references unless the context clearly indicates otherwise. Thus, for example, a reference to âa tubeâ includes a plurality of such tubes, as well as a single tube, and any equivalents thereof.
Throughout this description, including the foregoing description of related art, any and all publicly available documents described herein, including any and all U.S. patents, are specifically incorporated by reference herein in their entirety. Descriptions of related art are not intended in any way as an admission that any of the documents described therein, including pending applications for United States Patent, are prior art to the present invention. Moreover, the description herein of any disadvantages associated with the described products, methods, devices, systems and/or apparatus is not intended to limit the scope of the current subject matter. Indeed, aspects of the current subject matter can include certain features of the described products, methods, devices, systems and/or apparatus without suffering from their described disadvantages.
DESCRIPTION OF THE DRAWINGS
The accompanying drawings, which are incorporated in and constitute a part of this specification, show certain aspects of the subject matter disclosed herein and, together with the description, help explain some of the principles associated with the disclosed implementations. In the drawings,
FIG. 1 is a chart that shows co-secretion of amylin and insulin in response to meals in a healthy subject;
FIG. 2 is a chart that shows the decrease in fasting and post prandial glucose achieved with addition of pramlintide therapy;
FIG. 3 a is a schematic diagram that shows an infusion device comprising a dispensing unit that can deliver two therapeutic fluids as well as a remote control unit;
FIG. 3 b is a table diagram that shows an example of a dosing recommendation of pramlintide when given as an adjunctive therapy to insulin;
FIG. 4 a and FIG. 4 b are process flow diagrams illustrating methods for delivering therapeutic fluids for patient treatment;
FIG. 5 is a schematic diagram that shows a patch infusion device for delivering two therapeutic fluids that includes a housing having a disposable part;
FIG. 6 a , FIG. 6 b , and FIG. 6 c are schematic diagrams that show a patch infusion device including a cradle unit and a dispensing unit;
FIG. 7 a , FIG. 7 b , FIG. 7 c , and FIG. 7 d are schematic diagrams that show a cradle unit and dispensing unit of a patch infusion device;
FIG. 8 is a schematic diagram that shows a patch unit with a peristaltic pump as a first driving mechanism and a piston-type displacement pump as a second driving mechanism;
FIG. 9 is a schematic diagram that shows a patch unit in which the driving mechanism of both therapeutic fluids (such as for example insulin and pramlintide) is a piston-type displacement pump;
FIG. 10 is a schematic diagram that shows a two-fluid infusion device in which each fluid is delivered by an independent cannula, tube and associated reservoir, used a shared peristaltic pump;
FIG. 11 is a schematic diagram that shows an insulin and pramlintide infusion device in which each fluid comprises an independent peristaltic pump, cannula, tube and associated reservoir;
FIG. 12 is a schematic diagram that shows an insulin and pramlintide infusion device in which each fluid comprises an independent tube and associated reservoir, but share a common peristaltic pump and cannula;
FIG. 13 a and FIG. 13 b are schematic diagrams that show insulin and pramlintide infusion devices containing examples of continuous subcutaneous glucose monitors providing blood glucose readings (BG);
FIG. 14 is a schematic diagram that shows a device including an infusion patch unit for a first therapeutic fluid (such as for example insulin), an infusion patch unit for a second therapeutic fluid (such as for example pramlintide), and a remote control unit that communicates with both patch units;
FIG. 15 is a schematic diagram that shows a device including a first infusion patch unit composed of disposable and reusable parts, a second infusion patch unit, and a remote control unit that communicates with both patch units; and
FIG. 16 a , FIG. 16 b , and FIG. 16 c is a schematic diagram that shows three different configurations of an infusion device for delivering two therapeutic fluids including a remote control, infusion patch and a blood glucose monitor.
Wherever possible, the same reference numbers have been used throughout the drawings to refer to the same or like parts.
DETAILED DESCRIPTION
Currently, pump users who use additional diabetic drugs that are administered to the subcutaneous tissue (such as for example an amylin analog like pramlintide), cannot deliver the drugs concomitantly and are required to inject the non-insulin drug or drugs separately, a process that requires additional pricking which can often lead to poor compliance with a treatment regimen. Accordingly, there is a need for devices and/or methods capable of delivering more than one active substance into the body to achieve better glycemic control. The subject matter described herein can provide devices, apparatuses, systems, methods, techniques, and the like with advantages of that include, but are not limited to miniature, discreet, economical for the users and highly cost effective, that can deliver more than one active substance into the body to achieve better glycemic control. Devices according to the current subject matter can include a miniature infusion patch unit that can be adhered to the skin and that can deliver more than one active substance into the body. Such infusion patch units can be remotely controlled and can deliver more than one active substance into the body.
In some implementations, the dispensing device includes a sensor for measuring glucose levels. Such a sensor that can continuously monitor glucose level is provided, for example, in co-pending and co-owned U.S. application Ser. No. 11/989,678, filed 28 Jan. 2008 and entitled âFluid delivery system with optical sensing of analyte concentration levels,â the disclosure of which is hereby incorporated by reference. In some implementations, a dispensing patch unit can subcutaneously dispense glucagon, in addition to other diabetic agents, such as for example insulin. Endogenous glucagon secretion can be somewhat compromised in type 1 diabetes, since the (absent) β-cells are also themselves sensors for BG concentration (Diab. Tech. Therap. 2007; 9(2): 135-144). Glucagon is released whenever the patient is hypoglycemic or when hypoglycemia is impended (rapidly declining blood glucose levels), and acts as a counter-agent to insulin. The glucagon acts rapidly to prevent blood glucose excursions (i.e. deviation from blood glucose target zone) and thereby achieve normoglycemia. The infusion patch unit that can dispense glucagon and insulin can optionally work in a closed loop system.
The optimal amylin analog (for example pramlintide or the like) dosage can optionally be based on postprandial glucose measurements. In some examples, the goal of the ADA and the DCCT can be to keep glucose peak 2 hours after a meal below 180 mg/dL. If the goal is not reached, the device can recommend increasing the dosage.
Various implementations of the currently disclosed subject matter can provide infusion devices that include a miniature skin adherable infusion patch unit (also referred to herein as a âdispensing patchâ) that can in some examples be remotely controlled by a remote control unit. The dispensing patch can be discreet and free of inconvenient tubing and can dispense one or more therapeutic fluids, such as for example insulin and/or an amylin analog such as pramlintide from one or more reservoirs via one or more delivery tubes. Fluid motion can be urged by one or more pumping mechanisms, including but not limited to peristaltic pumps, piston-type displacement pumps, and the like. The dispensing patch can in some examples include a disposable part and a reusable part. The reusable part can optionally contain relatively expensive components of the dispensing patch (such as for example a peristaltic pump wheel, driving mechanism and electronics) and the disposable part can optionally contain relatively less expensive components (such as for example a delivery tube, reservoir, and the like). In this manner, a device can have relatively low ongoing operating costs for a user while being highly profitable for manufacturers and payers.
Dispensing patch units consistent with various aspects of the current subject matter can in some variations and implementations include one or more peristaltic pumping mechanisms (peristaltic pump). The peristaltic pump can optionally include a rotatable structure such as a wheel that includes one or more rollers, a stator and a delivery tube. The wheel and rollers can in some variations be located within a reusable part of the dispensing patch and a delivery tube and stator can be located within a disposable part. After disposable and reusable parts are properly paired, the wheel can be rotated and the rollers can squeeze the tube against the stator. Fluid delivery can thereby be maintained in the direction of rotation of the wheel. In some variations, a deformable reservoir that collapses and decreases in volume as fluid is withdrawn therefrom can be used in conjunction with a peristaltic pumping mechanism. Other variations and implementations can include a piston-type displacement pumping mechanism that includes a rigid or semi-rigid reservoir body and a plunger mechanism that can be moved to urge fluid out of the reservoir body.
FIG. 3 shows an implementation of the current subject matter that includes a dispending patch 1010 that can deliver two therapeutic fluids. The dispensing patch 1010 , can be adhered to the user's skin 5 . A remote control unit 1008 can communicate with the dispensing patch unit 1010 , thereby allowing programming, user inputs and data acquisition. Manual inputs of one or more of the therapeutic fluids deliverable from the dispensing patch unit 1010 can be carried out by buttons 10 located on the dispensing patch unit 1010 . The dispensing patch unit 1010 can include two housings
1001 , 1002 that contain reusable 1 and disposable 2 parts, respectively.
The disposable part 2 of the dispensing patch unit 1010 can contain two reservoirs
3 and 33 . If the dispensing patch unit 1010 is used to treat diabetic symptoms, a first reservoir 3 can contain insulin and a second reservoir 33 can contain pramlintide. Each reservoir can be associated with a cannula
6 , 66 that each penetrate the skin 5 to allow separate delivery of the two therapeutic fluids (for example insulin and pramlintide). The dispensing patch unit 1010 can be directly attached to the user's skin by adhesive means or some other attachment means such as for example a strap, or can be attached to a dedicated cradle unit that is adherable to the user's skin 5 and allows connection and disconnection of the patch unit 1010 as described in U.S. Provisional Patent Application No. 60/876,679, which is incorporated herein by reference in its entirety.
The relatively cheap components of the device, such as for example the two cannulae
6 and 66 can optionally reside in the disposable part 2 , while the relatively expensive components can optionally reside in the reusable part 1 . The delivered fluids can be insulin and any additional injectable therapeutic fluid that can be delivered to the subcutaneous tissue.
Manual inputs carried out by pressing at least one button 10 on the patch unit can cause delivery of a discrete amount of therapeutic fluid (e.g. insulin or pramlintide). According to some implementations, each pressing of the button can optionally deliver a predetermined dosage or quantum of the therapeutic fluid, and the user may determine the amount of quanta to be delivered by consecutive pressing of the button. Where delivery of pramlintide is carried out via a single pressing of the manual button 10 ), the delivered dose can optionally be 10% of the user's TDD of insulin. In some implementations, the button can comprise a pointer that may point to several different dosages (or different number of pramlintide quanta) and the user can determine the amount of quanta to be delivered by adjusting the pointer and then pressing of the button. The device can optionally recommend the optimal dosage of pramlintide. The user can then be able to accept or reject the recommendation. Alternatively, the dosage may be increased without user interface.
The dosage can be expressed as absolute values (e.g. each quantum or button press is equivalent to 2 units of pramlintide). Alternatively, the dosage can be expressed as percentage of TDD of insulin (e.g. each quantum or button press is equivalent to 5% of TDD).
Pramlintide dosages may be delivered using the remote control unit 1008 of the device. According to some implementations, the user may command administration of any dosage by inputting the value into the remote control unit. Alternatively the user may select a number of quanta of pramlintide to be delivered. In various implementations, the user may select the pramlintide dosage in accordance with the glycemic index (GI) and/or the carbohydrate load of the meal. In some implementations the pramlintide dosage may be chosen from within a grid 111 . An example of such a grid is shown in FIG. 3 b.
FIG. 4 a is a process flow diagram showing an example of dosing recommendations for amylin analog (Pramlintide) used as an adjunctive therapy to insulin. Dosing of pramlintide 400 is dependent on intended use. The intended use is determined at 402 . For weight loss at 404 , maximum doses can be preferred, while lower doses can be preferable when the goal is to normalize post-meal glucose levels at 406 .
In some implementations, a suitable dosing regime can include starting with a small dose, such as for example 2.5 units, and increasing the dose progressively, for example to 5 units, then 7.5 units, and 10 units, before each meal if no nausea is encountered for some set period of time, such as for example three days. However, different patients can require different doses, and therefore pramlintide doses are preferably individualized. According to some implementations, the dosage of pramlintide can be based on the amount of carbohydrates the user plans to consume and on the GI of the contemplated carbohydrates. The user can insert (for example into the remote control) the amount of carbohydrates and their correspondent GI. The optimal dosage of pramlintide for the specific user can then be delivered at 410 . In one example if the meal is expected to be smaller than a preset threshold (e.g. 250 Cal or 30 g carbohydrate), pramlintide may not be required at 412 . If this threshold or some other predetermined threshold is expected to be exceeded based on user input, pramlintide can be delivered.
If pramlintide is determined to be required a determination can be made at 414 whether the user is a first time user. If not, a method of determining an appropriate dose can be chosen at 416 . One option, at 420 is an insulin total daily dose (TDD) method in which the device delivers a discrete predetermined dosage of pramlintide at 422 , for example in multiples of some base dosage, which is calculated as percentage of TDD. In this example, 10% of the user's insulin TDD can be delivered as a bolus. The bolus can optionally be delivered by pressing the bolus button or buttons on a dispensing patch unit 1010 . For example if the TDD is 50 IU of insulin, each button press can deliver 5 units of pramlintide (3 presses=15 units of pramlintide). Bolus deliveries can also and/or alternatively be controlled using a remote control 1008 . An alternative method of determining the dose is according to meal glycemic index (GI) and carbohydrate content at 424 . A user can deliver the calculated exact amount of pramlintide in accordance with a table 426 such as that shown in FIG. 3 b . Delivery of the selected bolus can optionally be commanded by the remote control.
The optimal pramlintide dosages can also be based on postprandial glucose measurements at 430 . In one example, the goal can be to keep the blood glucose peak 2 hours after a meal below 180 mg dL â1 . If the goal is reached at 432 , it can be determined that the dosage or dosages are adequate for the user. If the goal is not reached at 434 , the dosage or dosages can be adjusted before the following meals.
If the use of pramlintide is initiated (i.e. first time user) at 434 , mealtime insulin with the first dose of pramlintide can optionally be reduced by some amount, for example by approximately 30-50%, to decrease the risk of hypoglycemia. Once pramlintide tolerability is established, basal and mealtime insulin doses can be adjusted, based on automatically or self-monitored bodily glucose values. Alternatively, the dosage may be increased without user interface.
For weight loss at 404 , larger amounts of pramlintide may be needed. The TDD can be determined at 436 . If TDD is greater than some threshold, for example 30U, at 440 , the user can be initiated with 2 units before the two or three largest meals of the day. If TDD is less than the threshold at 442 , the user can be initiated with 1 unit per meal. The dosages can then be increased by 1 unit per meal every three days as long as nausea is not present at 444 .
FIG. 4 b is a process flow chart 450 that shows a method for monitoring and controlling blood glucose levels. At 452 , a determination is made of required dosings of a first therapeutic fluid and a second therapeutic fluid for a user. In some implementations, insulin can be the first therapeutic fluid and an amylin analog such as pramlintide can be the second therapeutic fluid. The required dosing can be based on input data that can in some implementations optionally include data from a sensor that monitors one or more body chemistry indicators and/or activity data from a user that are input via a user interface. Such a user interface can include buttons on a delivery device, a remote control device, or the like, possibly (although not limited to) those described herein. At 454 , the first therapeutic fluid is delivered from a first reservoir. At 456 , the second therapeutic fluid is delivered from a second reservoir. At 460 , the efficacy of the dosing of the two therapeutic fluids is determined. In the example where the therapeutic fluids are insulin and pramlintide and continuous, discrete or semi-continuous monitoring of blood glucose is available, the determination of efficacy can include a determination of whether the patient's blood glucose level remained within a target range. Alternatively or in addition, user inputs regarding his/her perceptions or feelings can be usedâfor example if the user feels nauseous, light headed, or otherwise experiences symptoms of improperly elevated or depressed blood glucose, he/she can indicate this occurrence via a user interface such as buttons and/or a remote control. The required dosing can be adjusted based on the efficacy of the previous dosing. Dosing of the two fluids need not both be continuous. For example, insulin can be delivered at a basal level with occasional boluses while an amylin analog can be delivered as boluses timed to measured and/or anticipated excursions of blood glucose outside of desired ranges.
FIG. 5 shows a dispensing patch unit 1010 for delivering two therapeutic fluids. In some implementations, such a dispensing patch unit 1010 can be adhered to the user's skin 5 . The dispensing patch unit 1010 can include one housing 1002 that further includes a disposable part 2 . The dispensing patch unit 1010 can include a first reservoir 3 and a second reservoir 33 , one for each therapeutic fluid. In some examples, the two fluids can be insulin and an amylin analog. The first reservoir 3 is associated with a first cannula 6 and the second reservoir 33 is associated with a second cannula 66 . the two cannulae
6 and 66 each that penetrate the skin 5 to allow separate delivery of the two therapeutic fluids. Two bolus buttons
10 and 100 can be included on the dispensing patch unit 1010 to control boluses of each of the therapeutic fluids individually. For example, for insulin and an amylin analog, each button can be programmed to release a required, discrete pre-meal dosage.
In some implementations, insulin delivered via a dispensing patch unit 1010 such as those described herein can be rapid acting (such as for example Humalog) and be given as a pre-meal âfood bolusâ. Long acting insulin (such as for example Glargine, Detemire, etc.) can be injected once a day to meet the basal insulin requirements. The long acting insulin can be delivered via the same cannula as the rapid acting insulin, as detailed below in regards to FIG. 7 or separately at a different remote injection site.
In some implementations, several discrete bolus dosages can be selected and administered for each drug (e.g. low, medium and high dose). The selected bolus dosage of each drug is in accordance with numerous variable parameters such as carbohydrate load of the meal, the glycemic index of the carbohydrates in the meal, and contemplated physical activity. According to one such implementation, the dosages may be divided into predetermined quanta and each press on the bolus button may increase the dosage by one quantum.
FIG. 6 a , FIG. 6 b , and FIG. 6 c show dispensing patch units 1010 that include a cradle 300 unit and a dispensing patch unit. FIG. 6 a shows the cradle 300 unit of the dispensing patch unit 1010 . The cradle 300 can be a flat sheet with adhesive layer to be facing the skin and carrying a connection device or other connecting means on its upper side that allows connection and disconnection of the dispensing patch unit 1010 . Upon insertion of one or <figure-callout id="
CLAIMS
Claims ( 13 )
What is claimed is:
1. A portable therapeutic fluid delivery device having a form factor that permits ambulatory use by a user, the device comprising:
a first reservoir for containing a first therapeutic fluid;
a second reservoir for containing a second therapeutic fluid;
at least one cannula in fluid communication with the first and/or second reservoir, the at least one cannula being disposed to penetrate the user's skin to deliver the first and/or the second therapeutic fluid subcutaneously at a dosing rate;
at least one pumping mechanism that delivers the first therapeutic fluid from the first reservoir at a first dosing rate and delivers the second therapeutic fluid from the second reservoir at a second dosing rate to the at least one cannula and into the user;
a processor that controls the at least one pumping mechanism;
a disposable part; and
a reusable part configured to mate with the disposable part to form a dispensing patch unit, wherein the disposable part comprises a housing that contains the at least one cannula, the first reservoir, the second reservoir and a fluid delivery path between the cannula and at least one of the first and second reservoirs, wherein the cannula extends directly from the housing, and the reusable part comprises the processor and the at least one pumping mechanism.
2. The portable therapeutic fluid delivery device as in claim 1 , wherein the at least one cannula comprises a first cannula in fluid communication with the first reservoir and a second cannula in fluid communication with the second reservoir.
3. The portable therapeutic fluid delivery device as in claim 1 , wherein the first dosing rate is different from the second dosing rate.
4. The portable therapeutic fluid delivery device as in claim 1 , wherein the at least one pumping mechanism comprises a first pumping mechanism and a second pumping mechanism, the first pumping mechanism delivering the first fluid from the first reservoir and the second pumping mechanism delivering the second fluid from the second reservoir.
5. The portable therapeutic fluid delivery device as in claim 1 , wherein the first therapeutic fluid is insulin, and the first dosing rate comprises a basal dosing component and/or a bolus component.
6. The portable therapeutic fluid delivery device as in claim 1 , wherein the second therapeutic fluid is an amylin analog.
7. The portable therapeutic fluid delivery device as in claim 6 , wherein the amylin analog comprises pramlintide acetate.
8. The portable therapeutic fluid delivery device as in claim 1 , wherein the second therapeutic fluid is a glucagon.
9. The portable therapeutic fluid delivery device as in claim 1 , wherein the second therapeutic fluid is an exenatide.
10. The portable therapeutic fluid delivery device as in claim 6 , wherein the first and/or second dosing rate is based on expected calorie and/or carbohydrate intake by the user.
11. The portable therapeutic fluid delivery device as in claim 1 , wherein the at least one pumping mechanism comprises a peristaltic pumping mechanism.
12. The portable therapeutic fluid delivery device as in claim 1 , wherein the first reservoir and the second reservoir are coupled to a single housing.
13. The portable therapeutic fluid delivery device as in claim 1 , further comprising one or more buttons via which the user can adjust the first and/or the second dosing rate.
US14/857,991
2007-07-02
2015-09-18
Device for drug delivery
Active
2030-03-05
US10272199B2
( en )
Priority Applications (1)
Application Number
Priority Date
Filing Date
Title
US14/857,991
US10272199B2
( en )
2007-07-02
2015-09-18
Device for drug delivery
Applications Claiming Priority (4)
Application Number
Priority Date
Filing Date
Title
US95822007P
2007-07-02
2007-07-02
PCT/IL2008/000915
WO2009004627A2
( en )
2007-07-02
2008-07-02
A device for drug delivery
US45248410A
2010-01-04
2010-01-04
US14/857,991
US10272199B2
( en )
2007-07-02
2015-09-18
Device for drug delivery
Related Parent Applications (2)
Application Number
Title
Priority Date
Filing Date
PCT/IL2008/000915
Continuation
WO2009004627A2
( en )
2007-07-02
2008-07-02
A device for drug delivery
US12/452,484
Continuation
US9173991B2
( en )
2007-07-02
2008-07-02
Device for drug delivery
Publications (2)
Publication Number
Publication Date
US20160001002A1
US20160001002A1 ( en )
2016-01-07
US10272199B2
true
US10272199B2 ( en )
2019-04-30
Family
ID=39730643
Family Applications (2)
Application Number
Title
Priority Date
Filing Date
US12/452,484
Active
2030-12-15
US9173991B2
( en )
2007-07-02
2008-07-02
Device for drug delivery
US14/857,991
Active
2030-03-05
US10272199B2
( en )
2007-07-02
2015-09-18
Device for drug delivery
Family Applications Before (1)
Application Number
Title
Priority Date
Filing Date
US12/452,484
Active
2030-12-15
US9173991B2
( en )
2007-07-02
2008-07-02
Device for drug delivery
Country Status (5)
Country
Link
US
( 2 )
US9173991B2
( en )
EP
( 1 )
EP2173407B1
( en )
DK
( 1 )
DK2173407T3
( en )
ES
( 1 )
ES2785056T3
( en )
WO
( 1 )
WO2009004627A2
( en )
Cited By (1)
* Cited by examiner, â Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US12297825B2
( en )
2022-04-14
2025-05-13
Viking Pump, Inc.
Expandable, inner liner pump
Families Citing this family (158)
* Cited by examiner, â Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US8252321B2
( en )
2004-09-13
2012-08-28
Chrono Therapeutics, Inc.
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8956291B2
( en )
2005-02-22
2015-02-17
Admetsys Corporation
Balanced physiological monitoring and treatment system
PT1762259E
( en )
2005-09-12
2010-12-10
Unomedical As
INSERTER FOR AN INFUSION ASSEMBLY WITH A FIRST AND SECOND SPRING UNITS
US20080228056A1
( en )
2007-03-13
2008-09-18
Michael Blomquist
Basal rate testing using frequent blood glucose input
US7751907B2
( en )
2007-05-24
2010-07-06
Smiths Medical Asd, Inc.
Expert system for insulin pump therapy
US8221345B2
( en )
2007-05-30
2012-07-17
Smiths Medical Asd, Inc.
Insulin pump based expert system
ES2785056T3
( en )
*
2007-07-02
2020-10-05
Hoffmann La Roche
A device for drug delivery
US10420880B2
( en )
2007-10-02
2019-09-24
West Pharma. Services IL, Ltd.
Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US9656019B2
( en )
2007-10-02
2017-05-23
Medimop Medical Projects Ltd.
Apparatuses for securing components of a drug delivery system during transport and methods of using same
US7967795B1
( en )
2010-01-19
2011-06-28
Lamodel Ltd.
Cartridge interface assembly with driving plunger
US9173997B2
( en )
2007-10-02
2015-11-03
Medimop Medical Projects Ltd.
External drug pump
US9345836B2
( en )
2007-10-02
2016-05-24
Medimop Medical Projects Ltd.
Disengagement resistant telescoping assembly and unidirectional method of assembly for such
WO2009066287A2
( en )
2007-11-21
2009-05-28
Medingo Ltd.
Hypodermic optical monitoring of bodily analyte
JP2011504129A
( en )
*
2007-11-21
2011-02-03
ã¡ãã£ã³ã´ã»ãªãããã
Analyte monitoring and fluid dispensing system
AU2009203809B2
( en )
2008-01-09
2013-07-25
Sanofi-Aventis Deutschland Gmbh
Novel insulin derivatives having an extremely delayed time-action profile
US20090177142A1
( en )
2008-01-09
2009-07-09
Smiths Medical Md, Inc
Insulin pump with add-on modules
US8986253B2
( en )
2008-01-25
2015-03-24
Tandem Diabetes Care, Inc.
Two chamber pumps and related methods
WO2010011805A1
( en )
*
2008-07-24
2010-01-28
Admetsys Corporation
Device and method for automatically sampling and measuring blood analytes
US9393369B2
( en )
2008-09-15
2016-07-19
Medimop Medical Projects Ltd.
Stabilized pen injector
US12097357B2
( en )
2008-09-15
2024-09-24
West Pharma. Services IL, Ltd.
Stabilized pen injector
US8408421B2
( en )
2008-09-16
2013-04-02
Tandem Diabetes Care, Inc.
Flow regulating stopcocks and related methods
CA2737461A1
( en )
2008-09-19
2010-03-25
Tandem Diabetes Care, Inc.
Solute concentration measurement device and related methods
PT3228320T
( en )
2008-10-17
2020-03-26
Sanofi Aventis Deutschland
Combination of an insulin and a glp-1 agonist
US8152779B2
( en )
2008-12-30
2012-04-10
Medimop Medical Projects Ltd.
Needle assembly for drug pump
US9375529B2
( en )
2009-09-02
2016-06-28
Becton, Dickinson And Company
Extended use medical device
CA2753214C
( en )
2009-02-27
2017-07-25
Tandem Diabetes Care, Inc.
Methods and devices for determination of flow reservoir volume
US9250106B2
( en )
2009-02-27
2016-02-02
Tandem Diabetes Care, Inc.
Methods and devices for determination of flow reservoir volume
WO2010101621A1
( en )
2009-03-02
2010-09-10
Seventh Sense Biosystems, Inc.
Devices and methods for the analysis of an extractable medium
US9033898B2
( en )
2010-06-23
2015-05-19
Seventh Sense Biosystems, Inc.
Sampling devices and methods involving relatively little pain
US9295417B2
( en )
2011-04-29
2016-03-29
Seventh Sense Biosystems, Inc.
Systems and methods for collecting fluid from a subject
KR101853606B1
( en )
2009-07-06
2018-05-03
ì¬ë ¸í¼-ì벤í°ì¤ ëì´ì¹ ëí¸ ê²ì ë² í
Aqueous insulin preparations containing methionine
EP2724739B1
( en )
2009-07-30
2015-07-01
Tandem Diabetes Care, Inc.
Portable infusion pump system
US8157769B2
( en )
2009-09-15
2012-04-17
Medimop Medical Projects Ltd.
Cartridge insertion assembly for drug delivery system
US10071196B2
( en )
2012-05-15
2018-09-11
West Pharma. Services IL, Ltd.
Method for selectively powering a battery-operated drug-delivery device and device therefor
US10071198B2
( en )
2012-11-02
2018-09-11
West Pharma. Servicees IL, Ltd.
Adhesive structure for medical device
EP2482870B1
( en )
2009-09-29
2017-12-27
Admetsys Corporation
System and method for differentiating containers in medication delivery
EP2493536B1
( en )
*
2009-10-30
2017-09-20
Seventh Sense Biosystems, Inc.
Relatively small devices applied to the skin, modular systems, and methods of use thereof
KR101337322B1
( en )
2009-11-13
2013-12-06
ì¬ë ¸í¼-ì벤í°ì¤ ëì´ì¹ ëí¸ ê²ì ë² í
Pharmaceutical composition comprising a glp-1 agonist and methionine
DK2498802T3
( en )
2009-11-13
2015-04-13
Sanofi Aventis Deutschland
Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
EP2335755A1
( en )
2009-12-17
2011-06-22
Sanofi-Aventis Deutschland GmbH
Device and method for delivery of two or more drug agents
CA2689400C
( en )
*
2009-12-30
2023-01-10
Kenneth W. Adams
Therapeutic agent delivery apparatus and process
US8348898B2
( en )
2010-01-19
2013-01-08
Medimop Medical Projects Ltd.
Automatic needle for drug pump
WO2011094573A1
( en )
2010-01-28
2011-08-04
Seventh Sense Biosystems, Inc.
Monitoring or feedback systems and methods
US9662438B2
( en )
*
2010-02-05
2017-05-30
Deka Products Limited Partnership
Devices, methods and systems for wireless control of medical devices
JP2013523233A
( en )
2010-03-30
2013-06-17
ã¦ãã¡ãã£ã«ã« ã¢ã¯ãã£ã¼ã¼ã«ã¹ã«ã
Medical device
WO2011141907A1
( en )
2010-05-10
2011-11-17
Medimop Medical Projects Ltd.
Low volume accurate injector
JP2013538069A
( en )
2010-07-16
2013-10-10
ã»ãã³ã¹ ã»ã³ã¹ ãã¤ãªã·ã¹ãã ãºï¼ã¤ã³ã³ã¼ãã¬ã¼ããã
Low pressure environment for fluid transfer devices
US20120039809A1
( en )
2010-08-13
2012-02-16
Seventh Sense Biosystems, Inc.
Systems and techniques for monitoring subjects
ES2606554T3
( en )
2010-08-30
2017-03-24
Sanofi-Aventis Deutschland Gmbh
Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
EP2637562B1
( en )
2010-11-09
2016-01-27
Seventh Sense Biosystems, Inc.
Systems and interfaces for blood sampling
CA2820557A1
( en )
*
2010-11-29
2012-06-07
Sanofi-Aventis Deutschland Gmbh
Auto-injector device with a medicated module
US10194938B2
( en )
2011-03-14
2019-02-05
UnoMedical, AS
Inserter system with transport protection
USD702834S1
( en )
2011-03-22
2014-04-15
Medimop Medical Projects Ltd.
Cartridge for use in injection device
US20120249294A1
( en )
*
2011-03-29
2012-10-04
O'connor Sean
Biometric pairing for insulin infusion system
US20130158468A1
( en )
2011-12-19
2013-06-20
Seventh Sense Biosystems, Inc.
Delivering and/or receiving material with respect to a subject surface
JP2014516644A
( en )
2011-04-29
2014-07-17
ã»ãã³ã¹ ã»ã³ã¹ ãã¤ãªã·ã¹ãã ãºï¼ã¤ã³ã³ã¼ãã¬ã¼ããã
Devices and methods for collection and / or manipulation of blood spots or other body fluids
EP2701600B1
( en )
2011-04-29
2016-06-08
Seventh Sense Biosystems, Inc.
Delivering and/or receiving fluids
US9821032B2
( en )
2011-05-13
2017-11-21
Sanofi-Aventis Deutschland Gmbh
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130017259A1
( en )
2011-07-06
2013-01-17
The Parkinson's Institute
Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
PL2750699T3
( en )
2011-08-29
2015-12-31
Sanofi Aventis Deutschland
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1
( en )
2011-09-01
2014-04-16
Sanofi Aventis Deutschland
PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
EP2763723B1
( en )
2011-10-05
2016-04-13
Unomedical A/S
Inserter for simultaneous insertion of multiple transcutaneous parts
EP2583715A1
( en )
2011-10-19
2013-04-24
Unomedical A/S
Infusion tube system and method for manufacture
EP2809375B1
( en )
2012-01-31
2021-08-11
Medimop Medical Projects Ltd.
Time dependent drug delivery apparatus
EP3682871A1
( en )
*
2012-03-05
2020-07-22
Becton, Dickinson and Company
Apparatus for adhesive removal
US9072827B2
( en )
2012-03-26
2015-07-07
Medimop Medical Projects Ltd.
Fail safe point protector for needle safety flap
US10668213B2
( en )
2012-03-26
2020-06-02
West Pharma. Services IL, Ltd.
Motion activated mechanisms for a drug delivery device
US9463280B2
( en )
2012-03-26
2016-10-11
Medimop Medical Projects Ltd.
Motion activated septum puncturing drug delivery device
US9180242B2
( en )
2012-05-17
2015-11-10
Tandem Diabetes Care, Inc.
Methods and devices for multiple fluid transfer
US9867929B2
( en )
*
2012-08-15
2018-01-16
Becton, Dickinson And Company
Pump engine with metering system for dispensing liquid medication
US9421323B2
( en )
2013-01-03
2016-08-23
Medimop Medical Projects Ltd.
Door and doorstop for portable one use drug delivery apparatus
US10105487B2
( en )
2013-01-24
2018-10-23
Chrono Therapeutics Inc.
Optimized bio-synchronous bioactive agent delivery system
US9339604B1
( en )
*
2013-02-20
2016-05-17
MAAS Technologies Holding, LLC
Infusion systems with failure and alarm tolerant operating mode
US10201656B2
( en )
*
2013-03-13
2019-02-12
Tandem Diabetes Care, Inc.
Simplified insulin pump for type II diabetics
US9173998B2
( en )
2013-03-14
2015-11-03
Tandem Diabetes Care, Inc.
System and method for detecting occlusions in an infusion pump
US9492608B2
( en )
*
2013-03-15
2016-11-15
Tandem Diabetes Care, Inc.
Method and device utilizing insulin delivery protocols
US9011164B2
( en )
2013-04-30
2015-04-21
Medimop Medical Projects Ltd.
Clip contact for easy installation of printed circuit board PCB
US9889256B2
( en )
2013-05-03
2018-02-13
Medimop Medical Projects Ltd.
Sensing a status of an infuser based on sensing motor control and power input
EP3041528A4
( en )
2013-09-06
2017-04-26
Tandem Diabetes Care, Inc.
System and method for mitigating risk in automated medicament dosing
US10019555B2
( en )
2013-10-19
2018-07-10
Cohero Health, Inc.
Interactive respiratory device usage tracking system
US11424017B2
( en )
2013-10-19
2022-08-23
Aptargroup, Inc.
Respiratory system and method that monitors medication flow
WO2015061690A1
( en )
*
2013-10-24
2015-04-30
Trustees Of Boston University
Infusion system for preventing mischanneling of multiple medicaments
WO2015100439A1
( en )
2013-12-26
2015-07-02
Tandem Diabetes Care, Inc.
Integration of infusion pump with remote electronic device
US11135354B2
( en )
*
2014-03-03
2021-10-05
Quasuras, Inc.
Fluid delivery pump
US10004845B2
( en )
2014-04-18
2018-06-26
Becton, Dickinson And Company
Split piston metering pump
WO2015196174A1
( en )
*
2014-06-20
2015-12-23
Greene Howard E
Infusion delivery devices and methods
US9416775B2
( en )
2014-07-02
2016-08-16
Becton, Dickinson And Company
Internal cam metering pump
US11464899B2
( en )
2014-08-28
2022-10-11
Becton, Dickinson And Company
Wireless communication for on-body medical devices
AU2015359376B2
( en )
2014-12-12
2021-09-09
Sanofi-Aventis Deutschland Gmbh
Insulin glargine/lixisenatide fixed ratio formulation
WO2016123406A1
( en )
2015-01-28
2016-08-04
Chrono Therapeutics Inc.
Drug delivery methods and systems
US9795534B2
( en )
2015-03-04
2017-10-24
Medimop Medical Projects Ltd.
Compliant coupling assembly for cartridge coupling of a drug delivery device
US10251813B2
( en )
2015-03-04
2019-04-09
West Pharma. Services IL, Ltd.
Flexibly mounted cartridge alignment collar for drug delivery device
EP3267875A4
( en )
2015-03-12
2018-12-05
Chrono Therapeutics Inc.
Craving input and support system
TWI748945B
( en )
2015-03-13
2021-12-11
å¾·å賽諾è²é¿å¡ææ¯å¾·æå¿æéå ¬å¸
Treatment type 2 diabetes mellitus patients
TW201705975A
( en )
2015-03-18
2017-02-16
賽諾è²é¿å¡ææ¯å¾·æå¿æéå ¬å¸
Treatment of type 2 diabetes mellitus patients
EP3280468B1
( en )
*
2015-04-06
2019-11-06
Medela Holding AG
Improved breastmilk expression system with detection, feedback and connectability features
US10293120B2
( en )
2015-04-10
2019-05-21
West Pharma. Services IL, Ltd.
Redundant injection device status indication
US9744297B2
( en )
2015-04-10
2017-08-29
Medimop Medical Projects Ltd.
Needle cannula position as an input to operational control of an injection device
CN110013577A
( en )
*
2015-05-08
2019-07-16
以è²åä¸çº§è·³è¿æéè´£ä»»å ¬å¸
For to the systems, devices and methods being infused in vivo
US9993595B2
( en )
2015-05-18
2018-06-12
Tandem Diabetes Care, Inc.
Patch pump cartridge attachment
US10149943B2
( en )
2015-05-29
2018-12-11
West Pharma. Services IL, Ltd.
Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
EP3302652B1
( en )
2015-06-04
2023-09-06
Medimop Medical Projects Ltd.
Cartridge insertion for drug delivery device
US9820954B2
( en )
2015-08-19
2017-11-21
Jenivision Inc.
Quantitative peri-orbital application of ophthalmology drugs
US9987432B2
( en )
2015-09-22
2018-06-05
West Pharma. Services IL, Ltd.
Rotation resistant friction adapter for plunger driver of drug delivery device
US10576207B2
( en )
2015-10-09
2020-03-03
West Pharma. Services IL, Ltd.
Angled syringe patch injector
JP7017512B2
( en )
2015-10-09
2022-02-08
ã¦ã§ã¹ã ãã¡ã¼ã ãµã¼ãã·ã¼ãº ã¤ã¹ã©ã¨ã« ãªãããã
Bending fluid path type accessories for filled fluid containers
US10569016B2
( en )
2015-12-29
2020-02-25
Tandem Diabetes Care, Inc.
System and method for switching between closed loop and open loop control of an ambulatory infusion pump
EP4740989A2
( en )
2016-01-19
2026-05-13
Unomedical A/S
Cannula & infusion devices
US11311674B2
( en )
2016-01-21
2022-04-26
West Pharma. Services IL, Ltd.
Medicament delivery device comprising a visual indicator
EP3711793B1
( en )
2016-01-21
2021-12-01
West Pharma Services IL, Ltd.
A method of connecting a cartridge to an automatic injector
JP6542481B2
( en )
2016-01-21
2019-07-10
ã¦ã§ã¹ã ãã¡ã¼ã ãµã¼ãã·ã¼ãº ã¤ã¹ã©ã¨ã« ãªãããã
system
US11389597B2
( en )
2016-03-16
2022-07-19
West Pharma. Services IL, Ltd.
Staged telescopic screw assembly having different visual indicators
EP3463526B1
( en )
2016-06-02
2024-08-21
West Pharma. Services Il, Ltd.
Three position needle retraction
EP3978047B1
( en )
2016-08-01
2023-08-23
West Pharma Services IL, Ltd
Partial door closure prevention spring
EP3490643B1
( en )
2016-08-01
2021-10-27
West Pharma. Services Il, Ltd.
Anti-rotation cartridge pin
WO2018039577A1
( en )
*
2016-08-26
2018-03-01
Massachusetts Institute Of Technology
Bottlebrush polymers and uses thereof
WO2018067734A1
( en )
*
2016-10-04
2018-04-12
Craig M D H Randall
Medication delivery method and device with remote control
EP3562500B1
( en )
2016-12-27
2023-07-19
Adocia
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
WO2018129304A1
( en )
2017-01-06
2018-07-12
Chrono Therapeutics Inc.
Transdermal drug delivery devices and methods
US20200000756A1
( en )
*
2017-01-24
2020-01-02
Gt Biopharma, Inc.
Neostigmine combination and compositions
KR20180098009A
( en )
2017-02-24
2018-09-03
ì¼ì±ì ì주ìíì¬
Printed Circuit Board, and semiconductor package having the same
US11497851B2
( en )
2017-03-31
2022-11-15
Lifescan Ip Holdings, Llc
Maintaining maximum dosing limits for closed loop insulin management systems
US11147920B2
( en )
*
2017-04-18
2021-10-19
Lifescan Ip Holdings, Llc
Diabetes management system with automatic basal and manual bolus insulin control
EP3630226B1
( en )
2017-05-30
2025-10-22
West Pharma. Services Il, Ltd.
Modular drive train for wearable injector
CN119868710A
( en )
2017-06-15
2025-04-25
以è²åä¸çº§è·³è¿æéè´£ä»»å ¬å¸
Patch pump system and device for managing diabetes and method thereof
US11504472B2
( en )
2017-07-06
2022-11-22
Quasuras, Inc.
Medical pump with flow control
FR3082426A1
( en )
2018-06-14
2019-12-20
Adocia
COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
PL3658115T4